Modulus Discovery, Inc., an early stage global biopharmaceutical company with offices in Tokyo, Japan and Cambridge, MA, announced today the appointment of Yoh Terada, Ph.D., as Chief Scientific Officer of Modulus Discovery.

Dr. Terada joins Modulus from Astellas Pharma, where he worked for nearly twenty years in various senior disease biology R&D and management capacities. Terada most recently served as Director at Astellas Innovation Management, which is the collaboration research scouting and operations group in Cambridge, MA. Prior to this, he served as Visiting Scientist at Mitobridge in Cambridge, MA where he served as the liaison to Astellas and established and launched their portfolio of discovery programs from its inception, culminating in the successful closing of their recent $450M acquisition by Astellas. Throughout his career, Yoh has proposed and led over 25 discovery programs and delivered four IND compounds.

As Chief Scientific Officer and Head of Biology, Dr. Terada will be leading the establishment and operation of our pipeline of discovery programs. He will be working closely with our computational discovery platform team to manage both our internal programs as well as our external collaborations. Dr. Terada received his Ph.D. from Tokyo Medical and Dental University, and his M.S. from the University of Tokyo.

Comment from S. Roy Kimura, CEO, Modulus Discovery, Inc.
“We are very excited to welcome Dr. Yoh Terada as CSO of Modulus Discovery. Dr. Terada’s extensive experience starting and leading highly successful discovery programs in both large pharma and biotechnology venture settings will be a key asset for us going forward. We are looking forward to the further acceleration of our R&D efforts under Yoh’s leadership.”

Comment from Yoh Terada, CSO, Modulus Discovery, Inc.
“I’m thrilled to join to this exciting venture leveraging its state-of-the-art computational chemistry platform. Together with my experience in drug discovery research and management of virtual operation in both biotech and pharma companies, I’m confident that Modulus will achieve further acceleration in the delivery of innovative clinical candidates in the area of diseases with significant unmet medical needs.”